From Heart to Brain: Innovations in Cardiovascular and Stroke Research
A special issue of Healthcare (ISSN 2227-9032).
Deadline for manuscript submissions: 30 November 2024 | Viewed by 5403
Special Issue Editor
Interests: venous thromboembolism; stroke; thrombosis; coagulation; platelets; prevention; risk assessment; diabetes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Welcome to our Special Issue of “From Heart to Brain: Innovations in Cardiovascular and Stroke Research”. We seek to assess and publish groundbreaking research that explores cardiovascular and/or cerebrovascular disease from prevention, screening, diagnosis, or patient management perspectives. We are inviting researchers from diverse backgrounds to submit their quantitative, qualitative, or mixed-method research for publication (in open access). Studies using cutting-edge technologies and artificial intelligence are highly sought after. With your support, we aim to pave the way for groundbreaking advances in this field; this being the case, please join us in this exciting journey. Submissions of all types of manuscripts (clinical trials, cohort studies, case-control studies, case reports, review articles, etc.) will be received for peer review. The following are some topics of interest:
- Precision medicine in cardiovascular disease/stroke.
- Risk factors and risk assessment for cardiovascular disease/stroke.
- Role of inflammation in cardiovascular disease/stroke.
- Atherosclerosis.
- Thromboembolism.
- Coronary artery disease.
- Atrial fibrillation.
- Heart failure.
- Hypertension.
- Endovascular treatments.
- Imaging or non-imaging techniques.
- Psychosocial and emotional aspects of cardiovascular as well as stroke recovery and care.
- Innovations in stroke rehabilitation.
- Malignancies of the heart or brain.
For enquires, please contact the Guest Editor, Dr. Reza Mortazavi, at [email protected].
Dr. Reza Mortazavi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heart disease
- cardiovascular
- cerebrovascular accident
- diagnostic imaging
- prevention and control
- risk factors
- atrial fibrillation
- stroke
- ischemic, hemorrhagic, and precision medicine
- anticoagulation
- fibrinolysis
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Clinical characteristic, risk factors and outcomes of major adverse cardiovascular events in patients after a transient ischemic attack
Authors: Norman HY Lin1, Hon Jen Wong2, Yao Hao Teo1, Chen Ee Low2, Edward CY Lee3, Mark Y Chan2,3, Benjamin YQ Tan2,4, Leonard LL Yeo2,4, Ching-Hui Sia2, 3
Affiliation: 1 Department of Medicine, National University Hospital, Singapore
2 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
3 Department of Cardiology, National University Heart Centre, Singapore
4 Division of Neurology, Department of Medicine, National University Hospital, Singapore
Abstract: Introduction: Patients who develop transient ischemic attack are at risk of developing major adverse cardiovascular events. Contemporary data on the predictors of MACE in TIA patients remain scarce. With stroke and ischemic heart attack being the leading causes of death worldwide, identifying TIA patients at risk of developing MACE allows for a focus in secondary prevention efforts. Methods: A single-center retrospective observational study involving a multi-ethnic Asian cohort was conducted. Data from 149 consecutive patients with neurologist- and neuroimaging-adjudicated transient ischemic attack from 2012-2020 were extracted from the electronic medical record. Baseline characteristics, past medical history, blood tests values, TIA symptoms distribution, and outcomes were obtained. Continuous variables as mean (SD) and compared between groups via Mann-Whitney U test. Categorical variables presented as number (%) and compared with Pearson’s chi-squared test or Fisher’s exact test. Logistic regression was used to model the association with MACE in relation to one or more explanatory variables. Results: In the overall cohort of patients with a history of TIA, 101 (67.8%) were male and the mean age was 59.3 (SD 12.7). A total of 31 out of 149 patients experienced MACE. There was no significant difference in age, sex, race, diabetes mellitus, hypertension, hyperlipidemia, smoking history and left ventricular ejection fraction (LVEF) when comparing patients who developed MACE after TIA. The incidence of various symptoms during the initial TIA did not differ between groups. A history of TIA (OR 5.33 95%CI 1.42-20.9), systolic blood pressure ≥150 mmHg (OR 2.46 95% 1.02-6.24), LVEF <50% (OR 5.06 95% 1.08-23.8) were independently associated with MACE after adjustment. Conclusions:
Patients who developed MACE after TIA were similar to those who did not develop MACE in terms of baseline characteristics. A history of TIA, SBP ≥150 mmHg and LVEF <50% were associated with MACE after TIA.
Title: Emergence of Atrial Fibrillation and Flutter in COVID-19: A Retrospective Cohort Study
Authors: Tanzim Bhuiya1, Paras P. Shah2, Wing Hang Lau3, Timothy Park3, Rezwan F. Munshi3, Ofek Hai3, Roman Zeltser3, and Amgad N. Makaryus2,3
Affiliation: 1 Hospital of the University of Pennsylvania, Philadelphia, PA, USA
2 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
3 Department of Cardiology, Nassau University Medical Center, East Meadow, NY, USA
Abstract: COVID-19 is associated with various cardiovascular complications, including arrhythmias. This study investigated the incidence of new-onset atrial fibrillation (AFB) and atrial flutter (AFL) in COVID-19 patients and identified potential risk factors. We conducted a retrospective cohort study at a tertiary-care community including 647 patients diagnosed with COVID-19 from March 2020 to March 2021. Patients with a prior history of AFB or AFL were excluded. Data on demographics, clinical characteristics, and outcomes were collected and analyzed using chi-square tests, t-tests, and binary logistic regression.
We found that 69 patients (10.66%) developed AFB or AFL, with 41 patients (6.34%) experiencing new-onset arrhythmias. The incidence rates for new-onset AFB and AFL were 5.4% and 0.9%, respectively. Older age (≥65 years) and sepsis were significantly associated with new-onset AFB/AFL, with odds ratios of 5.43 and 2.73, respectively. No significant association was found with patient sex.
Our findings indicate that new-onset atrial arrhythmias are a significant complication in COVID-19 patients, particularly among the elderly and those with sepsis. This highlights the need for targeted monitoring and management strategies to mitigate the burden of atrial arrhythmias in high-risk populations during COVID-19 infection.